Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis

Linda Stein Gold,David Pariser,Jerry Bagel,Marie L Osterdal,Zhenyi Xu,Paul Yamauchi

doi:10.25251/skin.2.supp.24

Abstract

Highlights

A foam formulation of fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g has been developed as a treatment option for patients with psoriasis1The Phase III PSO-FAST (Cal/BD foam in PSOriasis vulgaris, a Four-week, vehicle-controlled, efficacy And Safety Trial) study demonstrated that calcipotriol μg/g (Cal)/BD foam provides significantly greater efficacy than vehicle in patients with psoriasis2Itch is a common and distressing aspect of psoriasis that negatively impacts on a patient’s quality of life, causing discomfort, potentially aggravating the lesion, and often leading to sleep loss3,4In this sub-analysis of the PSO-FAST study we assessed changes in itch during treatment with Cal/BD foam, in patients who had clinically relevant itch at baseline5
323 patients were randomized to Cal/BD foam, and 103 to vehicle
Treatment groups were generally well balanced in terms of demographic and baseline factors, the gender balance was different between Cal/BD foam and vehicle (Table 1)

Summary

Introduction

A foam formulation of fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed as a treatment option for patients with psoriasis1The Phase III PSO-FAST (Cal/BD foam in PSOriasis vulgaris, a Four-week, vehicle-controlled, efficacy And Safety Trial) study demonstrated that Cal/BD foam provides significantly greater efficacy than vehicle in patients with psoriasis2Itch is a common and distressing aspect of psoriasis that negatively impacts on a patient’s quality of life, causing discomfort, potentially aggravating the lesion, and often leading to sleep loss3,4In this sub-analysis of the PSO-FAST study we assessed changes in itch during treatment with Cal/BD foam, in patients who had clinically relevant itch at baseline (defined as visual analogue scale [VAS] score of >30). A foam formulation of fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed as a treatment option for patients with psoriasis. Itch is a common and distressing aspect of psoriasis that negatively impacts on a patient’s quality of life, causing discomfort, potentially aggravating the lesion, and often leading to sleep loss. Itch is a common and distressing aspect of psoriasis that negatively impacts on a patient’s quality of life, causing discomfort, potentially aggravating the lesion, and often leading to sleep loss3,4 In this sub-analysis of the PSO-FAST study we assessed changes in itch during treatment with Cal/BD foam, in patients who had clinically relevant itch at baseline (defined as visual analogue scale [VAS] score of >30)

Methods

Results

Conclusion